Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538]
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-11-01
|
| Series: | Heliyon |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844022026925 |
| _version_ | 1797988096358219776 |
|---|---|
| author | Lei Zhao Nijia Chang Lei Shi Fengyi Li Fanglin Meng Xiaohui Xie Zhe Xu Fusheng Wang |
| author_facet | Lei Zhao Nijia Chang Lei Shi Fengyi Li Fanglin Meng Xiaohui Xie Zhe Xu Fusheng Wang |
| author_sort | Lei Zhao |
| collection | DOAJ |
| first_indexed | 2024-04-11T07:57:30Z |
| format | Article |
| id | doaj.art-e3b07fa540f14077b53e4639b67508cb |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-04-11T07:57:30Z |
| publishDate | 2022-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-e3b07fa540f14077b53e4639b67508cb2022-12-22T04:35:53ZengElsevierHeliyon2405-84402022-11-01811e11404Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538]Lei Zhao0Nijia Chang1Lei Shi2Fengyi Li3Fanglin Meng4Xiaohui Xie5Zhe Xu6Fusheng Wang7Medical school of Chinese PLA, Chinese PLA General Hospital, Beijing, 100853, China; Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, 100039, ChinaThe Second Medical Center of PLA General Hospital, Beijing, 100039, ChinaTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, 100039, ChinaTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, 100039, ChinaTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, 100039, ChinaTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, 100039, ChinaTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, 100039, China; Corresponding author.Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, 100039, China; Corresponding author.http://www.sciencedirect.com/science/article/pii/S2405844022026925 |
| spellingShingle | Lei Zhao Nijia Chang Lei Shi Fengyi Li Fanglin Meng Xiaohui Xie Zhe Xu Fusheng Wang Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538] Heliyon |
| title | Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538] |
| title_full | Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538] |
| title_fullStr | Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538] |
| title_full_unstemmed | Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538] |
| title_short | Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538] |
| title_sort | corrigendum to lenvatinib plus sintilimab versus lenvatinib monotherapy as first line treatment for advanced hbv related hepatocellular carcinoma a retrospective real world study heliyon 8 6 2022 e09538 |
| url | http://www.sciencedirect.com/science/article/pii/S2405844022026925 |
| work_keys_str_mv | AT leizhao corrigendumtolenvatinibplussintilimabversuslenvatinibmonotherapyasfirstlinetreatmentforadvancedhbvrelatedhepatocellularcarcinomaaretrospectiverealworldstudyheliyon862022e09538 AT nijiachang corrigendumtolenvatinibplussintilimabversuslenvatinibmonotherapyasfirstlinetreatmentforadvancedhbvrelatedhepatocellularcarcinomaaretrospectiverealworldstudyheliyon862022e09538 AT leishi corrigendumtolenvatinibplussintilimabversuslenvatinibmonotherapyasfirstlinetreatmentforadvancedhbvrelatedhepatocellularcarcinomaaretrospectiverealworldstudyheliyon862022e09538 AT fengyili corrigendumtolenvatinibplussintilimabversuslenvatinibmonotherapyasfirstlinetreatmentforadvancedhbvrelatedhepatocellularcarcinomaaretrospectiverealworldstudyheliyon862022e09538 AT fanglinmeng corrigendumtolenvatinibplussintilimabversuslenvatinibmonotherapyasfirstlinetreatmentforadvancedhbvrelatedhepatocellularcarcinomaaretrospectiverealworldstudyheliyon862022e09538 AT xiaohuixie corrigendumtolenvatinibplussintilimabversuslenvatinibmonotherapyasfirstlinetreatmentforadvancedhbvrelatedhepatocellularcarcinomaaretrospectiverealworldstudyheliyon862022e09538 AT zhexu corrigendumtolenvatinibplussintilimabversuslenvatinibmonotherapyasfirstlinetreatmentforadvancedhbvrelatedhepatocellularcarcinomaaretrospectiverealworldstudyheliyon862022e09538 AT fushengwang corrigendumtolenvatinibplussintilimabversuslenvatinibmonotherapyasfirstlinetreatmentforadvancedhbvrelatedhepatocellularcarcinomaaretrospectiverealworldstudyheliyon862022e09538 |